Long-Chain Polyphosphate Is a Potential Agent for Inducing Mucosal Healing of the Colon in Ulcerative Colitis.

2019-11-20
Clinical pharmacology and therapeutics 107(2)

PubMed: 31513280
DOI: 10.1002/cpt.1628

Study Design

Type: Clinical Trial
Population: 10 enrolled patients
Methods: The first-in-human trial showed that long-chain polyphosphate was administered; antiinflammatory effects were also demonstrated in a human macrophage and interleukin-10 knockout transfusion mouse model.

The goal of ulcerative colitis (UC) treatment has recently been shown to be "mucosal healing," as no drug directly induces mucosal healing. Probiotics possess sufficient safety, but their efficacy in the treatment of UC remains controversial because of the influence of intestinal conditions. It is believed that the identification of bioactive molecules produced by probiotics and their application will help to solve this issue. We therefore identified a probiotic-derived long-chain polyphosphate as a molecule enhancing the intestinal barrier function. This study demonstrated that long-chain polyphosphate exhibited antiinflammatory effects in a human macrophage and interleukin-10 knockout transfusion mouse model. The first-in-human trial showed that 7 of the 10 enrolled patients acquired clinical remission, 4 of whom achieved endoscopic remission despite a history of treatment with anti-tumor necrosis factor (TNF)-α agents. No adverse reactions were observed. Long-chain polyphosphate might be useful for the treatment of refractory UC, even in patients with failure or intolerance to anti-TNF-α therapy.

Research Insights

Supplement	Dose	Health Outcome	Effect Type	Effect Size	Source
Lactobacillus brevis SBC8803	—	Improved Mucosal Healing	Beneficial	Large	View source Long-chain polyphosphate is a potential agent for inducing mucosal healing of the colon in ulcerative colitis.
Lactobacillus brevis SBC8803	—	Maintained Remission in Ulcerative Colitis	Beneficial	Large	View source The first-in-human trial showed that 7 of the 10 enrolled patients acquired clinical remission, 4 of whom achieved endoscopic remission despite a history of treatment with anti-tumor necrosis factor (TNF)-α agents.